IL199904A - Preparations containing medicinal and alkoxy-polyethylene glycol and their uses - Google Patents

Preparations containing medicinal and alkoxy-polyethylene glycol and their uses

Info

Publication number
IL199904A
IL199904A IL199904A IL19990409A IL199904A IL 199904 A IL199904 A IL 199904A IL 199904 A IL199904 A IL 199904A IL 19990409 A IL19990409 A IL 19990409A IL 199904 A IL199904 A IL 199904A
Authority
IL
Israel
Prior art keywords
alkoxy
compositions
polyethylene glycol
therapeutic agent
therapeutic
Prior art date
Application number
IL199904A
Other languages
English (en)
Hebrew (he)
Other versions
IL199904A0 (en
Original Assignee
Hananja Ehf
Univ Iceland
Intranasal Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hananja Ehf, Univ Iceland, Intranasal Therapeutics filed Critical Hananja Ehf
Publication of IL199904A0 publication Critical patent/IL199904A0/en
Publication of IL199904A publication Critical patent/IL199904A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL199904A 2007-01-19 2009-07-16 Preparations containing medicinal and alkoxy-polyethylene glycol and their uses IL199904A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IS8593 2007-01-19
PCT/US2008/051466 WO2008089426A2 (en) 2007-01-19 2008-01-18 Methods and compositions for the delivery of a therapeutic agent

Publications (2)

Publication Number Publication Date
IL199904A0 IL199904A0 (en) 2010-04-15
IL199904A true IL199904A (en) 2014-07-31

Family

ID=39512543

Family Applications (1)

Application Number Title Priority Date Filing Date
IL199904A IL199904A (en) 2007-01-19 2009-07-16 Preparations containing medicinal and alkoxy-polyethylene glycol and their uses

Country Status (11)

Country Link
EP (2) EP2121025B1 (enExample)
JP (5) JP5877939B2 (enExample)
CN (3) CN106389330A (enExample)
AU (1) AU2008206105B2 (enExample)
CA (1) CA2676010C (enExample)
DK (1) DK2121025T3 (enExample)
ES (1) ES2611995T3 (enExample)
HU (1) HUE031463T2 (enExample)
IL (1) IL199904A (enExample)
PL (1) PL2121025T3 (enExample)
WO (1) WO2008089426A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0720716D0 (en) * 2007-10-23 2007-12-05 York Pharma Plc Novel formulation
GB2481407B (en) * 2010-06-22 2012-05-23 Special Products Ltd A rapid onset liquid midazolam composition for buccal administration
SMT201800105T1 (it) * 2011-05-13 2018-05-02 Euro Celtique Sa Forme posologiche farmaceutiche intranasali comprendenti naloxone
EP3681474B1 (en) * 2017-09-11 2025-10-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions and methods for nasal administration of drugs to brain and for systemic effect
JP2019099557A (ja) * 2017-11-28 2019-06-24 日本化薬株式会社 ベンダムスチンを含有する溶液製剤
WO2019226753A1 (en) 2018-05-25 2019-11-28 Ucb Biopharma Sprl Benzodiazepine formulations
CN111388481A (zh) * 2020-03-20 2020-07-10 浙江美华鼎昌医药科技有限公司 一种咪达唑仑和丙戊酸钠的药物组合物及其制备方法
CN114588116B (zh) * 2020-12-04 2024-03-15 四川科瑞德制药股份有限公司 磷苯妥英钠固体组合物、冻干方法、及其用途
CN113274482B (zh) * 2021-06-07 2023-09-05 穆琳 缩宫素或其衍生物在制备治疗或改善贫乳的制剂中的用途以及组合物
WO2024142091A1 (en) * 2022-12-26 2024-07-04 Cipla Limited Stable aqueous injectable formulation of flucytosine
WO2025115019A1 (en) * 2023-11-30 2025-06-05 Padagis Israel Pharmaceuticals Ltd. Stable nitroglycerin formulations

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4153689A (en) 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
WO1987005210A1 (fr) * 1986-03-10 1987-09-11 Kurt Burghart Produit pharmaceutique et son procede de preparation
US4782047A (en) 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
DE3734306A1 (de) 1987-10-10 1989-04-27 Pfeiffer Erich Gmbh & Co Kg Austragvorrichtung fuer fliessfaehige medien
EP0532546B1 (en) 1990-05-10 1998-03-18 Bechgaard International Research And Development A/S A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
US5338732A (en) * 1991-06-18 1994-08-16 Bristol-Myers Squibb Company Megestrol acetate formulation
GB9125699D0 (en) 1991-12-03 1992-01-29 Glaxo Group Ltd Device
US5897880A (en) * 1995-09-29 1999-04-27 Lam Pharmaceuticals, Llc. Topical drug preparations
HUP9903942A3 (en) * 1996-07-03 2000-07-28 Alza Corp Non-aqueous protic peptide formulations
CA2379365C (en) * 1999-07-26 2009-11-17 Sk Corporation Transnasal anticonvulsive compositions and modulated process
KR100360827B1 (ko) * 1999-08-14 2002-11-18 주식회사 삼양사 난용성 약물을 가용화하기 위한 고분자 조성물 및 그의 제조방법
KR100345214B1 (ko) * 1999-08-17 2002-07-25 이강춘 생체적합성 고분자가 수식된 펩타이드의 비점막 전달
DE19940236A1 (de) 1999-08-25 2001-03-08 Pfeiffer Erich Gmbh & Co Kg Spender mit manuell betätigbarer Ausbringeinrichtung
US20020037319A1 (en) * 1999-11-08 2002-03-28 Alan Drizen Drug preparations
US6610271B2 (en) * 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6948492B2 (en) 2000-08-15 2005-09-27 University Of Kentucky Research Foundation Programmable multi-dose intranasal drug delivery device
WO2003099264A1 (en) * 2002-05-23 2003-12-04 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
JP4542743B2 (ja) * 2002-12-26 2010-09-15 Ｋｄｌ株式会社 ピリドン誘導体の溶液状医薬組成物
JP2007070225A (ja) * 2003-07-25 2007-03-22 Yukako Fujinaga クロストリジウム属菌由来成分を含む医薬製剤
WO2005027977A2 (en) * 2003-09-22 2005-03-31 Agis Industries (1983) Ltd. Diclofenac compositions for the treatment of skin disorders
US20050244517A1 (en) * 2003-11-05 2005-11-03 Santarus, Inc. Combination of proton pump inhibitor and sleep aid
GB0400804D0 (en) * 2004-01-14 2004-02-18 Innoscience Technology Bv Pharmaceutical compositions
JP4746856B2 (ja) * 2004-08-12 2011-08-10 三笠製薬株式会社 ピラゾロン系製剤
US20060110415A1 (en) * 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
EP1848403B8 (en) * 2005-01-14 2010-05-19 Camurus Ab Topical bioadhesive formulations
US20070021411A1 (en) * 2005-05-11 2007-01-25 Cloyd James C Supersaturated benzodiazepine solutions and their delivery
TW200824693A (en) * 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
KR20090087079A (ko) * 2006-11-21 2009-08-14 노파르티스 아게 벤조디아제핀 구조의 ｒｓｖ 억제제를 포함하는 안정한 비경구 제형

Also Published As

Publication number Publication date
HUE031463T2 (en) 2017-07-28
DK2121025T3 (en) 2017-01-30
CN101678112B (zh) 2016-08-31
AU2008206105A1 (en) 2008-07-24
ES2611995T3 (es) 2017-05-11
JP2017048250A (ja) 2017-03-09
JP2016029117A (ja) 2016-03-03
CN106420614A (zh) 2017-02-22
JP2013231089A (ja) 2013-11-14
CA2676010A1 (en) 2008-07-24
EP2121025B1 (en) 2016-11-02
JP5877939B2 (ja) 2016-03-08
WO2008089426A2 (en) 2008-07-24
EP3150230A1 (en) 2017-04-05
JP6295314B2 (ja) 2018-03-14
CN106389330A (zh) 2017-02-15
JP2017155060A (ja) 2017-09-07
JP2010516696A (ja) 2010-05-20
JP6084277B2 (ja) 2017-02-22
CN101678112A (zh) 2010-03-24
AU2008206105B2 (en) 2014-04-03
EP2121025A2 (en) 2009-11-25
CA2676010C (en) 2016-05-17
PL2121025T3 (pl) 2017-09-29
WO2008089426A3 (en) 2009-02-12
IL199904A0 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
IL199904A0 (en) Compositions comprising a therapeutic agent and an alkoxy-polyethylene glycol and uses thereof
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
AP2965A (en) Therapeutic compositions and the use thereof
GB0621957D0 (en) Inhaler devices and bespoke pharmaceutical compositions
AP2490A (en) Therapeutic compositions and the use thereof
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL184563A (en) Pharmaceutical foam formulations and their use
IL245513A0 (en) Medical preparations containing ingenol-3-angelate
ZA200904935B (en) Benefit agent delivery compositions
EP2219554A4 (en) PROGESTER-CONTAINING COMPOSITIONS AND DEVICES
IL220618B (en) Hemostatic preparations and treatment regimens
PL2154966T3 (pl) Benzoimidazole i ich kompozycje farmaceutyczne
GB2443336B (en) Spiruchostatin analogues and their medicinal use
IL197235A0 (en) Therapeutic compositions
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
PL2012805T3 (pl) Kompozycja lecznicza i jej zastosowanie
IL200274A0 (en) Pharmaceutical compositions comprising a calcilytic agent
GB0715428D0 (en) Compositions and uses thereof
PL2236145T3 (pl) Kompozycja farmaceutyczna i lek złożony
GB0701170D0 (en) Compositions and uses thereof
GB0614365D0 (en) Pharmaceutical compositions and their use
EP2010141A4 (en) NUCLEOTIDE COMPOSITIONS HAVING HIGH DEPOSITS AND USES THEREOF
GB0701171D0 (en) Compositions and uses thereof
GB0725264D0 (en) Compositions and uses thereof
HU0600097D0 (en) Pharmaceutical composition comprising tacrolimus

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees
KB Patent renewed
KB Patent renewed